Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Barnaby HuntMaarten van der Vliet

Abstract

Insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single pen injection device, and a once-daily treatment option for patients with type 2 diabetes mellitus (T2DM) who are uncontrolled on basal insulin and require treatment intensification. The objective of this analysis was to evaluate the long-term cost-effectiveness of IDegLira versus basal-bolus therapy (insulin glargine U100 + 3× daily insulin aspart) for patients with T2DM uncontrolled on basal insulin [HbA1c >53 mmol/mol (>7%)] in the Netherlands. Cost-effectiveness analysis was performed using the validated IMS CORE Diabetes Model from a healthcare payer perspective. Outcomes were modeled over patient lifetimes in a cohort with baseline characteristics from the DUAL™ II trial. Treatment effect data were sourced from a statistical indirect comparison (pooled analysis) of IDegLira with basal-bolus therapy. Treatment with IDegLira resulted in mean increases in quality-adjusted life expectancy of 0.43 quality-adjusted life years versus basal-bolus therapy. Improved clinical outcomes resulted from fewer diabetes-related complications and a delayed time to their onset. IDegLira was associated with lo...Continue Reading

References

Jun 8, 2000·Medical Care·T O Tengs, A Wallace
Aug 25, 2004·Current Medical Research and Opinion·Andrew J PalmerGiatgen A Spinas
Aug 31, 2004·Diabetes Care·UNKNOWN American Diabetes Association Consensus Panel
Aug 1, 2006·Health Policy and Planning·Franco Sassi
Nov 9, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Cornelis BoersmaMaarten J Postma
Jun 28, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Sofia DiasA E Ades
Aug 13, 2014·Diabetes Care·John B BuseUNKNOWN NN9068-3912 (DUAL-II) Trial Investigators
Sep 23, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Phil McEwanDavid Grant
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·M BøgelundN Schaper
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·J OverbeekR Herings
Nov 20, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Nick FreemantleStephen C Bain

❮ Previous
Next ❯

Citations

Oct 25, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Milan KvapilBarnaby Hunt
Feb 2, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Johannes PöhlmannBarnaby Hunt

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01392573
NCT01952145

Software Mentioned

DUALVII
IDegLira

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.